biostudies-literatureUnknown15(1)Guieze RRichter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle oNature communications6822https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316063biostudies-literatureBlinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.PMC11316063Lazarian GQuittet PQuinquenel AMolina LClavert AMichallet ASRouille VSchwartz DSaad AAurran THivert BBroseus JRoos-Weil DMagnin BFornecker LMTournilhac OYsebaert LPereira BGuieze RFerrant Ede Guibert SDrenou BLaribi Kde Antonio MFeugier PLaurent CVeronese LGay JfalseBlinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle o2024-01-01T00:00:00Z2024 Aug2026-06-01T07:23:18.366Z2024-12-03T15:09:10.567ZS-EPMC113160633912271710.1038/s41467-024-51264-2